Andrea Rigoni

[Charlotte Kuperwasser, PhD @KUPERWASSERLAB]

We are now in a situation where the new mRNA platforms are being deployed at scale, without proper short-term or long-term human data. Some say it is simply because that data does not yet exist, and others say it is because that data is not being shared.

Because of the innovations in mRNA technology, it places a higher burden on ongoing monitoring, open scientific inquiry, and responsiveness to signals, however preliminary.

If federal agencies (@US_FDA , @CDCgov) are not actively engaging with these questions, or are perceived as unresponsive, then we are left with a difficult position:

We are continuing to use current products, and developing future ones, while key uncertainties remain incompletely characterized.

That is not an argument against these technologies. It is an argument for stronger, more transparent science and regulation.

Constructive engagement should not mean defending prior decisions. It should mean actively interrogating them, improving surveillance, and ensuring that emerging risks are identified early rather than debated after the fact.

Public trust is not built by controlling narratives. It is built by showing that no question is off limits when it comes to safety.

@VPrasadMDMPH @DrJBhattacharya @NIHDirector_Jay @DrMakaryFDA @TracyBethHoeg @RobertKennedyJr @RetsefL @MartinKulldorff

[Framework @FrameworkPuter]

The new gpt-oss-120b from @OpenAI is now the best general purpose model to run on a Framework Desktop! ~40 tok/s on the MXFP4 version in @lmstudio on Fedora 42.